ANAPC5 mRNA水平表达上调在肝细胞肝癌中的临床价值及相关通路分析

doi:10.3969/j.issn.1009-976X.2023.03.004

岭南现代临床外科 ›› 2023, Vol. 23 ›› Issue (03): 230-237.DOI: 10.3969/j.issn.1009-976X.2023.03.004

ANAPC5 mRNA水平表达上调在肝细胞肝癌中的临床价值及相关通路分析

吴薇紫¹, 张观兰², 唐宇星², 郑青¹, 陈瑜¹, 陈吉添¹, 詹彦婷², 莫伟嘉^2,*

1.广西钦州市灵山县人民医院病理科,广西钦州 535400;
2.广西医科大学第一附属医院病理科,广西南宁 530021

通讯作者: *莫伟嘉,Email：gxmumoweijia@163.com
基金资助:
广西壮族自治区卫生健康委员会科研课题（Z20190523; Z20190594）; 广西高校创新创业训练计划项目（S202210598190X）

Clinical value of up-regulated expression of ANAPC5 mRNA in hepatocellular carinnoma and analysis of related pathways

WU Wei-zi¹, ZHANG Guan-lan², TANG Yu-xing², ZHENG Qing¹, CHEN Yu¹, CHEN Ji-tian¹, ZHAN Yan-ting², MO Wei-jia²

1. Department of Pathology, Lingshan County People′s Hospital, Qinzhou, Guangxi 535400, China;
2. Department of Pathology, the First Affiliated Hospital of Guangxi Medical University,Nanning 530021, China

Received:2022-06-13 Published:2023-08-04
Contact: MO Wei-jia, gxmumoweijia@163.com

摘要/Abstract

摘要： 目的探讨ANAPC5表达趋势及临床价值以及该分子在肝细胞癌（HCC）进展中参与的潜在生物学机制。方法联合来自世界范围内的HCC基因芯片及mRNA测序数据,使用Wilcoxon检验,通过合并标准化平均差（SMD）分析ANAPC5在肝细胞癌组织中的综合表达状况,评估其在肝细胞肝癌组中的临床价值及潜在参与的相关生物学通路。结果通过分析3820个HCC样本和3091个正常样本的高通量数据的结果,SMD=0.71（95%CI：0.55~0.88）。SROC曲线下面积为0.81,根据诊断试验结果,敏感度为0.69（95%CI：0.60~0.77）,特异度为0.81（95%CI：0.73~0.88）,阳性似然比为3.78（95%CI：2.63~5.47）,阴性似然比为0.39（95%CI：0.29~0.48）。富集分析结果显示,ANAPC5与核糖体、剪接体、细胞周期等通路相关。结论 ANAPC5上调在HCC中可能发挥促癌作用。

关键词: 肝细胞肝癌, ANAPC5, 临床价值, 通路分析

Abstract: Objective To explore the expression trend and clinical value of ANAPC5 as well as the potential molecular mechanism of ANAPC5 involving in the progression of HCC. Methods Combined with HCC gene microarrays and RNA-seq data worldwide, Wilcoxon test was used to analyze the comprehensive expression of ANAPC5 in HCC by combining SMD. Simultaneously, its clinical value and related pathway analysis in HCC was evaluated. Results By analyzing the results of gene microarray or RNA-seq data of 3820 HCC samples and 3091 non-HCC samples, the combined SMD=0.71（95%CI： 0.55~0.88）, with obvious heterogeneity. The AUC=0.81, sensitivity=0.69 （95%CI： 0.60~0.77）, specificity= 0.81（95%CI： 0.73~0.88）, positive likelihood ratio= 3.78 （95%CI： 2.63~5.47）, negative likelihood ratio=0.39 （95%CI： 0.29~0.48）. Enrichment analysis showed that ANAPC5 was related to ribosome, spliceosome, cell cycle pathways. Conclusion Up_regulation of ANAPC5 may play a role in promoting HCC development.

Key words: hepatocellular carcinoma, ANAPC5, clinical value, pathway analysis

中图分类号:

R735.7

吴薇紫, 张观兰, 唐宇星, 郑青, 陈瑜, 陈吉添, 詹彦婷, 莫伟嘉. ANAPC5 mRNA水平表达上调在肝细胞肝癌中的临床价值及相关通路分析[J]. 岭南现代临床外科, 2023, 23(03): 230-237.

WU Wei-zi, ZHANG Guan-lan, TANG Yu-xing, ZHENG Qing, CHEN Yu, CHEN Ji-tian, ZHAN Yan-ting, MO Wei-jia. Clinical value of up-regulated expression of ANAPC5 mRNA in hepatocellular carinnoma and analysis of related pathways[J]. Lingnan Modern Clinics In Surgery, 2023, 23(03): 230-237.

参考文献

[1] 熊世泽, 刘伟. 二甲双胍对肝细胞癌的诊断、预防及治疗作用[J]. 中南大学学报(医学版), 2022, 47(3): 364-373.
[2] 张春双, 蔡靖. 晚期肝细胞癌的分子靶向及免疫检查点治疗[J]. 中西医结合肝病杂志, 2022, 32(4): 377-381.
[3] Hui AM, Makuuchi M, Li X.Cell cycle regulators and human hepatocarcinogenesis[J]. Hepatogastroenterology, 1998, 45(23): 1635-1642.
[4] Schrock MS, Stromberg BR, Scarberry L, Summers MK.APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis[J]. Semin Cancer Biol, 2020, 67(Pt 2): 80-91.
[5] Rahimi H, Ahmadzadeh A, Yousef-amoli S, et al. The expression pattern of APC2 and APC7 in various cancer cell lines and AML patients[J]. Adv Med Sci, 2015, 60(2): 259-263.
[6] Zhou J, Zhang S, Fu G, et al.Overexpression of APC11 predicts worse survival in lung adenocarcinoma[J]. Onco Targets Ther, 2018, 11: 7125-7132.
[7] VanGenderen C, Harkness TAA, Arnason TG. The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression[J]. Aging (Albany NY), 2020, 12(15): 15818-15855.
[8] Dang F, Nie L, Wei W.Ubiquitin signaling in cell cycle control and tumorigenesis[J]. Cell Death Differ, 2021, 28(2): 427-438.
[9] Wang W, Chen J, Hu D, et al.SARS-CoV-2 N Protein Induces Acute Kidney Injury via Smad3-Dependent G1 Cell Cycle Arrest Mechanism[J]. Adv Sci (Weinh), 2022, 9(3): e2103248.
[10] Tutuncuoglu B, Cakir M, Batra J, et al.The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2[J]. Cancer Discov, 2020, 10(7): 916-921.
[11] Wang L, Zhang J, Wan L, et al.Targeting Cdc20 as a novel cancer therapeutic strategy[J]. Pharmacol Ther, 2015, 151: 141-151.
[12] Lub S, Maes A, Maes K, et al.Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells[J]. Oncotarget, 2016, 7(4): 4062-4076.
[13] Gao Y, Zhang B, Wang Y, Shang G.Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells[J]. Oncol Rep, 2018, 40(2): 841-848.

ANAPC5 mRNA水平表达上调在肝细胞肝癌中的临床价值及相关通路分析

Clinical value of up-regulated expression of ANAPC5 mRNA in hepatocellular carinnoma and analysis of related pathways

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

[1]	程诺, 任庆旗, 袁建玲, 吴柳盛, 林泽伟. 术前外周血循环肿瘤DNA在肝细胞癌微循环血管侵犯预测中的应用价值分析[J]. 岭南现代临床外科, 2023, 23(02): 100-105.
[2]	黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(01): 110-114.
[3]	宋燕州, 康志龙, 苏一男, 张毅明, 赵新, 李志伟, 李伟. NEK7在原发性肝细胞肝癌患者中表达及其临床意义[J]. 岭南现代临床外科, 2021, 21(06): 608-613.
[4]	苏汝平, 李妮, 钟漓, 赵志. 腹腔镜肝切除联合脾动脉结扎术治疗肝癌合并门脉高压症的疗效分析[J]. 岭南现代临床外科, 2021, 21(04): 415-418.
[5]	赵兵兵，李梓涛，胡伟东，薛静，李明意*. 肝细胞肝癌的早期诊断与精准治疗[J]. 岭南现代临床外科, 2018, 18(05): 593-598.
[6]	王礼东袁晓东骆必伟谢勇田佩凯欧希林泽伟刘晓平刘吉奎陈心春张明霞. 中央记忆T细胞和效应记忆T细胞亚群在肝癌患者外周血中分布特点分析[J]. 岭南现代临床外科, 2016, 16(03): 249-253.
[7]	许侨东颜永聪黄拼搏喻志敏肖治宇. 原发性肝细胞肝癌中PinX1的表达及其临床意义[J]. 岭南现代临床外科, 2016, 16(02): 223-227.
[8]	吴海丰. 腹腔镜肝切除术在治疗肝癌的安全性及疗效分析[J]. 岭南现代临床外科, 2016, 16(01): 24-26.
[9]	胡志刚王捷. 精准医疗时代肝细胞肝癌诊疗策略[J]. 岭南现代临床外科, 2016, 16(01): 1-6.
[10]	陈捷叶义标罗兴喜张金岱鲁振环吴潇陈涛. 术后中性粒细胞／淋巴细胞比值变化对肝细胞肝癌切除术后患者预后的影响[J]. 岭南现代临床外科, 2014, 14(05): 509-512.
[11]	黄治国,黄拼搏,何传超,肖治宇. FAP-1在肝细胞肝癌中的表达及临床意义[J]. 岭南现代临床外科, 2013, 13(02): 91-94.